Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4CAR T Cells for Relapsed/Refractory AML as Bridge to Transplant
NCT06197672Phase 1Suspended
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD4CAR in acute myeloid leukemia (AML). Primary endpoints: Maximum Tolerated Dose at Day 28, Persistence and biologic behavior of CD4CAR at Day 28 and 2 more. Started Mar 2024; status: suspended.
02
Drugs
CD4CAR
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06197672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06197672.